OS Therapies Completes Exercise Inducement and Exchange Offer for All Remaining Outstanding Warrants Issued in Connection with December 2024 Financing
OS Therapies (NYSE American: OSTX) has successfully completed a warrant exchange offer with holders of outstanding warrants originally issued in December 2024. The transaction raised $3.7 million in gross proceeds through the exercise of warrants with a $1.12 per share exercise price.
The new warrants issued have an exercise price of $3.00 per share with a forced exercise provision triggered when the stock trades above $9.00. The proceeds will primarily fund commercial preparations for OST-HER2, targeting prevention of recurrent pulmonary metastatic osteosarcoma. The company now has funding extended into 2027, with potential for additional $20 million if the forced exercise provision is triggered.
OS Therapies (NYSE American: OSTX) ha completato con successo un’offerta di scambio di warrant con i detentori dei warrant emessi nel dicembre 2024. L’operazione ha raccolto 3,7 milioni di dollari di proventi lordi attraverso l’esercizio di warrant con prezzo di esercizio di 1,12$ per azione.
I nuovi warrant hanno un prezzo di esercizio di 3,00$ per azione e prevedono una clausola di esercizio forzato se il titolo supera i 9,00$. I proventi saranno utilizzati principalmente per le attività commerciali preparatorie di OST-HER2, mirato alla prevenzione delle recidive di osteosarcoma polmonare metastatico. La società ha ora finanziamenti estesi fino al 2027, con la possibilità di ulteriori 20 milioni di dollari se scatta la clausola di esercizio forzato.
OS Therapies (NYSE American: OSTX) ha concluido con éxito una oferta de canje de warrants con los tenedores de los warrants emitidos en diciembre de 2024. La transacción generó 3,7 millones de dólares en ingresos brutos mediante el ejercicio de warrants con un precio de ejercicio de 1,12$ por acción.
Los nuevos warrants tienen un precio de ejercicio de 3,00$ por acción y una cláusula de ejercicio forzoso que se activa si la acción cotiza por encima de 9,00$. Los fondos se destinarán principalmente a los preparativos comerciales de OST-HER2, dirigido a prevenir la recaída del osteosarcoma metastásico pulmonar. La compañía cuenta ahora con financiación extendida hasta 2027, con la posibilidad de otros 20 millones de dólares si se activa el ejercicio forzoso.
OS Therapies (NYSE American: OSTX)는 2024년 12월에 발행된 워런트 보유자들과의 워런트 교환 제안을 성공적으로 완료했습니다. 해당 거래를 통해 행사가 1.12달러인 워런트 행사로 총 370만 달러의 브루트 조달을 달성했습니다.
신규 워런트의 행사가격은 주당 3.00달러이며, 주가가 9.00달러를 초과할 경우 강제 행사 조항이 발동됩니다. 조달금은 주로 재발성 폐 전이성 골육종 예방을 목표로 한 OST-HER2의 상업화 준비에 사용될 예정입니다. 회사는 이제 2027년까지 자금 확보가 연장되었고, 강제 행사 조항이 발동될 경우 추가로 2,000만 달러를 확보할 가능성이 있습니다.
OS Therapies (NYSE American: OSTX) a terminé avec succès une offre d’échange de bons de souscription (warrants) avec les détenteurs des warrants émis en décembre 2024. La transaction a généré 3,7 millions de dollars de produits bruts grâce à l’exercice de warrants au prix d’exercice de 1,12$ par action.
Les nouveaux warrants émis ont un prix d’exercice de 3,00$ par action et comportent une clause d’exercice forcé déclenchée si le titre cote au-dessus de 9,00$. Les fonds serviront principalement à financer les préparatifs commerciaux d’OST-HER2, destiné à prévenir les récidives d’ostéosarcome métastatique pulmonaire. La société bénéficie désormais d’un financement prolongé jusqu’en 2027, avec la possibilité d’obtenir 20 millions de dollars supplémentaires si la clause d’exercice forcé est activée.
OS Therapies (NYSE American: OSTX) hat ein Warrant-Tauschangebot mit den Inhabern der ursprünglich im Dezember 2024 ausgegebenen Warrants erfolgreich abgeschlossen. Durch die Ausübung von Warrants mit einem Ausübungspreis von 1,12$ pro Aktie wurden 3,7 Millionen US-Dollar Bruttoerlös erzielt.
Die ausgegebenen neuen Warrants haben einen Ausübungspreis von 3,00$ pro Aktie und enthalten eine Zwangsausübungsregel, die greift, wenn die Aktie über 9,00$ handelt. Die Erlöse sollen vorwiegend die kommerziellen Vorbereitungen für OST-HER2 finanzieren, das auf die Verhinderung rezidivierender pulmonaler metastasierender Osteosarkome abzielt. Das Unternehmen verfügt nun über Finanzierung bis ins Jahr 2027 sowie die Möglichkeit zusätzlicher 20 Millionen US-Dollar, falls die Zwangsausübung eintritt.
- None.
- Dilution from warrant exercise and potential future warrant conversions
- Dependency on stock price reaching $9.00 for forced warrant exercise
Insights
OS Therapies raised $3.7M through warrant exchanges, extending runway to 2027 and potentially securing another $20M for commercialization and pipeline expansion.
OS Therapies has successfully completed a strategic financial maneuver through a warrant exchange that has generated
The immediate financial impact is substantial. The company has extended its cash runway into 2027, providing crucial operational stability. Management plans to use these funds to accelerate commercial preparations for OST-HER2 in treating fully resected, pulmonary metastatic osteosarcoma, potentially pulling forward commercialization to early 2026 pending FDA approval.
Beyond the balance sheet strengthening, this transaction addresses potential market dynamics by eliminating low-priced warrants (
If the company executes successfully and triggers the forced exercise provision at
- All remaining holders of outstanding warrants with
$1.12 per share exercise price have participated, raising$3.7 million in gross proceeds to be used to accelerate OST-HER2 commercial launch preparations - New warrants issued have an exercise price of
$3.00 per share with a forced exercise provision when the stock trades above$9.00
New York, New York--(Newsfile Corp. - September 2, 2025) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today announced that it has completed a warrant inducement and exchange offer with the holders of all remaining outstanding warrants with an exercise price
"Given the highly productive meeting we just completed with FDA, we remain confident in our ability to rapidly bring OST-HER2 to patients," said Paul Romness, MPH, Chairman & CEO of OS Therapies. "Completing this transaction positions us to bring forward into early 2026 the timing of potential commercialization of OST-HER2 in the United States, subject to regulatory approval by FDA."
Mr. Romness continued, "In parallel, eliminating existing warrants with an exercise price of
Ceros Financial Services, Inc. acted as the exclusive warrant solicitation agent for the transaction.
About OS Therapies
OS Therapies is a clinical stage oncology company focused on the identification, development, and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. OST-HER2, the Company's lead asset, is an immunotherapy leveraging the immune-stimulatory effects of Listeria bacteria to initiate a strong immune response targeting the HER2 protein. OST-HER2 has received Rare Pediatric Disease Designation (RPDD) from the U.S. Food & Drug Administration and Fast-Track and Orphan Drug designations from the U.S. FDA and European Medicines Agency. The Company reported positive data in its Phase 2b clinical trial of OST-HER2 in recurrent, fully resected, lung metastatic osteosarcoma, demonstrating statistically significant benefit in the 12-month event free survival (EFS) primary endpoint of the study. The Company anticipates submitting a Biologics Licensing Application (BLA) to the U.S. FDA for OST-HER2 in osteosarcoma in 2025 and, if approved, would become eligible to receive a Priority Review Voucher that it could then sell. OST-HER2 has completed a Phase 1 clinical study primarily in breast cancer patients, in addition to showing preclinical efficacy data in various models of breast cancer. OST-HER2 has been conditionally approved by the U.S. Department of Agriculture for the treatment of canines with osteosarcoma.
In addition, OS Therapies is advancing its next-generation Antibody Drug Conjugate (ADC) and Drug Conjugates (DC), known as tunable ADC (tADC), which features tunable, tailored antibody-linker-payload candidates. This platform leverages the Company's proprietary silicone Si-Linker and Conditionally Active Payload (CAP) technology, enabling the delivery of multiple payloads per linker. For more information, please visit www.ostherapies.com.
Forward-Looking Statements
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute forward-looking statements within the meaning of the federal securities laws. These forward-looking statements and terms such as "anticipate," "expect," "intend," "may," "will," "should" or other comparable terms involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Those statements include statements regarding the intent, belief or current expectations of OS Therapies and members of its management, as well as the assumptions on which such statements are based. OS Therapies cautions readers that forward-looking statements are based on management's expectations and assumptions as of the date of this press release and are subject to certain risks and uncertainties that could cause actual results to differ materially, including, but not limited to the approval of OST-HER2 by the U.S. FDA and other risks and uncertainties described in "Risk Factors" in the Company's most recent Annual Report on Form 10-K, most recent Quarterly Report on Form 10-Q and other subsequent documents the Company files with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and, except as required by the federal securities laws, OS Therapies specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
OS Therapies Contact Information:
Investor Relations
Harrison Seidner, PhD
WaterSeid Partners
OSTX@waterseid.com
Public Relations
Stephanie Chen
Elev8 New Media
stephanie@elev8newmedia.com
https://x.com/OSTherapies
https://www.instagram.com/ostherapies/
https://www.facebook.com/OSTherapies/
https://www.linkedin.com/company/os-therapies/
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/264694
FAQ
How much did OS Therapies (OSTX) raise in the warrant exchange offer?
What is the exercise price of OSTX's new warrants?
How long will the funding last for OS Therapies (OSTX)?
What will OS Therapies use the warrant exchange proceeds for?
How much additional funding could OSTX receive if the new warrants are exercised?
